Page 27 - Demo

2Phase I clinical trial to determine the feasibility and maximum tolerated dose of panitumumab to standard gemcitabine-based chemoradiation in locally advanced pancreatic cancerClinical Cancer Research. 2015 Oct 15;21(20):4569-75Annette A. van Zweeden1, Hans J.van der Vliet1, Johanna W. Wilmink2, Martijn R. Meijerink3, Otto W.M. Meijer4, Anna M.E. Bruynzeel4, Geertjan van Tienhoven5, Elisa Giovannetti1, Geert Kazemier6 , Maarten A.J.M. Jacobs7, and Henk M.W. Verheul11 Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands. 2Department of Medical Oncology, Academic Medical Center, Amsterdam, the Netherlands. 3 Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands. 4Department of Radiation Oncology, VU University Medical Center, Amsterdam, the Netherlands. 5Department of Radiation Oncology, Academic Medical Center, Amsterdam, the Netherlands. 6 Department of Surgery, VU University Medical Center, Amsterdam, the Netherlands. 7 Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands. Corresponding Author: Henk Verheul, VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, the Netherlands. Phone: 31-20-4444321; Fax: 31- 20-4444355; E-mail: h.verheul@vumc.nl